ANTI CATHEPSIN B MARKET ANALYSIS

Regional Analysis

Global Anti-Cathepsin B Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global anti-cathepsin B market over the forecast period, owing to increasing research and development in anti-cathepsin B. For instance, on November 11, 2020, Spandidos Publications announced in stem-like cells from pancreatic cancer, cathepsin B is strongly expressed and is linked to surgical success in patients. Western blotting was used to demonstrate that the lysosomal cysteine protease cathepsin B (CTSB) was highly elevated in PCSLCs in comparison to that in the parental cells. Additionally, flow cytometry research proved that PCSLCs' surface expression of CTSB was higher than that of parental cells. Additionally, compared to the parental cells, PCLCs secreted more CTSB from their cells. In 69 resected tumor specimens, CTSB expression was assessed, and high expression was related to the clinicopathological characteristics of the patients and surgical results.

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East: GCC, Israel, and Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa